Letrozole

The dosage of Letrozole is strictly determined by the indication being treated. According to the FDA-approved prescribing information:

• Breast Cancer (Adjuvant, Extended Adjuvant, or Metastatic): The standard recommended dose is 2.5 mg taken once daily. In the adjuvant setting, the optimal duration of treatment is often 5 years, although some clinical trials (such as the MA.17R study) have explored extended use for up to 10 years to maximize disease-free survival.
• Ovulation Induction (Off-Label): For fertility purposes, healthcare providers typically prescribe 2.5 mg to 5 mg daily for 5 consecutive days, usually starting on day 3, 4, or 5 of the menstrual cycle.

Letrozole is not FDA-approved for use in pediatric patients. While it has been studied off-label for conditions such as precocious puberty (early puberty) and short stature in adolescent males (to delay bone age maturation), the safety and efficacy in these populations have not been formally established. The FDA warns that Letrozole may cause premature fusion of the growth plates in children, potentially leading to shorter adult height than expected.

Renal Impairment

No dosage adjustment is required for patients with mild to moderate renal impairment (Creatinine Clearance ≥ 10 mL/min). However, Letrozole has not been extensively studied in patients with a CrCl of less than 10 mL/min, and caution is advised in these cases.

Hepatic Impairment

For patients with mild to moderate hepatic impairment (Child-Pugh score A or B), no dose adjustment is generally necessary. However, in patients with severe hepatic impairment (Child-Pugh score C), the dose should be reduced or the interval between doses increased. Some clinicians recommend a dose of 2.5 mg every other day for these patients due to the significantly increased systemic exposure (AUC).

Elderly Patients

No specific dose adjustments are required for elderly patients. Clinical trials included a significant number of patients aged 65 and older, and no overall differences in safety or effectiveness were observed compared to younger postmenopausal women.

To ensure the maximum efficacy of Letrozole, patients should follow these administration guidelines:

1. 1Consistency: Take the medication at the same time every day to maintain steady levels in the bloodstream.
2. 2Food: Letrozole can be taken with or without food. If the medication causes stomach upset, taking it with a meal may help.
3. 3Swallow Whole: The tablets should be swallowed whole with a glass of water. Do not crush, chew, or break the tablets unless specifically instructed by your doctor, as this may affect the drug's absorption rate.
4. 4Storage: Store the medication at room temperature (20°C to 25°C / 68°F to 77°F), away from moisture, heat, and direct sunlight. Keep the bottle tightly closed.

If you miss a dose of Letrozole, take it as soon as you remember. However, if it is almost time for your next scheduled dose (within 12 hours), skip the missed dose and return to your regular schedule. Do not 'double up' or take two doses at once to make up for a missed one. Frequent missed doses can reduce the effectiveness of the treatment in preventing cancer recurrence.

There is limited clinical experience with Letrozole overdose. In animal studies, high doses led to ataxia (loss of coordination) and dyspnea (difficulty breathing). If an overdose is suspected, contact a Poison Control Center (1-800-222-1222) or seek emergency medical attention immediately. Treatment is generally supportive, as there is no specific antidote for Letrozole.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without first consulting your medical team.

Because Letrozole significantly lowers estrogen levels, many of its side effects mimic the symptoms of menopause. These are often most pronounced during the first few months of therapy.

• Hot Flashes and Flushing: Sudden feelings of warmth, often intense, usually over the face and neck. These occur in approximately 18-33% of patients.
• Arthralgia (Joint Pain): This is one of the most common reasons for treatment discontinuation. Patients often report stiffness and pain in the hands, knees, or hips, particularly in the morning. This is sometimes referred to as 'AI-induced musculoskeletal syndrome' (AIMSS).
• Fatigue: A general sense of tiredness or lack of energy that does not improve with rest.
• Increased Sweating (Hyperhidrosis): Often associated with night sweats.
• Hypercholesterolemia: An increase in cholesterol levels is common, requiring regular monitoring of lipid profiles.

• Headache and Dizziness: Some patients report mild to moderate lightheadedness.
• Gastrointestinal Issues: This includes nausea, constipation, or diarrhea.
• Weight Changes: Many patients experience weight gain, though weight loss is also possible.
• Thinning Hair (Alopecia): While not as severe as chemotherapy-induced hair loss, many women notice a reduction in hair density.
• Edema: Swelling of the feet, ankles, or hands due to fluid retention.

• Cataracts: Some studies have suggested a slightly increased risk of lens opacity.
• Leukopenia: A decrease in white blood cell counts, which may increase the risk of infection.
• Skin Rash: Including erythema or maculopapular eruptions.

> Warning: Stop taking Letrozole and call your doctor immediately if you experience any of the following symptoms:

• Thromboembolic Events: Signs of a blood clot, such as sudden shortness of breath, chest pain, or swelling and redness in one leg. Letrozole may slightly increase the risk of stroke or pulmonary embolism.
• Severe Allergic Reaction (Anaphylaxis): Symptoms include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.
• Hepatotoxicity (Liver Damage): Yellowing of the skin or eyes (jaundice), dark urine, or severe upper abdominal pain.
• Cardiac Events: New or worsening chest pain (angina) or signs of a heart attack.
• Bone Fractures: Sudden, intense pain in the back, hip, or wrist, which may indicate a fracture due to decreased bone mineral density.

Bone Health (Osteoporosis)

Estrogen plays a vital role in maintaining bone density. Because Letrozole profoundly suppresses estrogen, long-term use is associated with a significant decrease in bone mineral density (BMD). According to data from the BIG 1-98 trial, patients taking Letrozole have a higher rate of osteoporosis and clinical bone fractures compared to those taking tamoxifen. Healthcare providers typically recommend baseline and periodic DEXA (Dual-Energy X-ray Absorptiometry) scans to monitor bone health. Supplemental calcium and Vitamin D, or the use of bisphosphonates (like zoledronic acid), are often prescribed alongside Letrozole.

Cardiovascular Health

Long-term estrogen deprivation can affect lipid metabolism and vascular health. Patients should be monitored for increases in total cholesterol and LDL levels. There is also a small but noted increase in the risk of ischemic cardiovascular events in patients with pre-existing heart disease.

There are currently no FDA black box warnings for Letrozole. However, the FDA does include a 'Contraindications' and 'Warnings and Precautions' section regarding Embryo-Fetal Toxicity. Letrozole can cause fetal harm when administered to a pregnant woman. If the drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Letrozole is a potent hormonal medication that requires careful medical supervision. It is exclusively intended for women who are in a postmenopausal state, unless being used for specific off-label fertility treatments under the guidance of a reproductive endocrinologist. Verification of postmenopausal status (through blood tests for FSH and estradiol levels) is often required before starting therapy for breast cancer.

As of 2026, there are no FDA black box warnings for Letrozole. However, it carries significant warnings regarding pregnancy and bone health that are treated with the same level of clinical gravity as a boxed warning.

Embryo-Fetal Toxicity

Letrozole is strictly contraindicated in women who are pregnant. It is classified as a drug that can cause significant birth defects or fetal death. Women of childbearing potential who are using Letrozole off-label for fertility must be closely monitored to ensure the drug is not taken once pregnancy has occurred. For cancer patients, effective non-hormonal contraception must be used if there is any chance of pregnancy.

Bone Mineral Density Loss

Decreased bone mineral density is a primary concern. The reduction in estrogen leads to accelerated bone resorption. Patients with pre-existing osteoporosis or a high risk of fractures should be evaluated carefully. Treatment with bone-strengthening agents (e.g., denosumab or bisphosphonates) is frequently initiated in conjunction with Letrozole therapy.

Hepatic Impairment

In patients with severe hepatic cirrhosis, Letrozole levels can double, leading to increased toxicity. These patients require close monitoring and potential dose adjustments. Liver function tests (LFTs) should be performed if symptoms of liver dysfunction appear.

Cholesterol Elevations

Letrozole can cause significant increases in serum cholesterol. In clinical trials, approximately 50% of patients experienced an increase in total cholesterol. Routine lipid monitoring is recommended, and lipid-lowering therapy (such as statins) may be necessary.

Patients on long-term Letrozole therapy typically require the following monitoring schedule:

1. 1Bone Density: DEXA scans every 1-2 years.
2. 2Lipid Profile: Annual fasting blood tests for cholesterol and triglycerides.
3. 3Liver Function: Periodic blood tests if the patient has a history of liver disease.
4. 4Clinical Assessment: Regular physical exams to check for signs of cancer recurrence or cardiovascular issues.

Letrozole may cause fatigue, dizziness, and somnolence (sleepiness). Patients should observe how the medication affects them before driving or operating heavy machinery. If you experience significant dizziness, avoid these activities and contact your doctor.

There is no direct contraindication between Letrozole and moderate alcohol consumption. However, alcohol can exacerbate certain side effects like hot flashes and dizziness. Furthermore, because both Letrozole and alcohol are processed by the liver, excessive drinking should be avoided to prevent unnecessary hepatic stress.

Do not stop taking Letrozole without consulting your oncologist. In the context of breast cancer, stopping the medication early significantly increases the risk of the cancer returning. There is no 'withdrawal syndrome' associated with Letrozole, but the therapeutic benefit is lost immediately upon discontinuation.

> Important: Discuss all your medical conditions, especially any history of osteoporosis or liver disease, with your healthcare provider before starting Letrozole.

• Estrogen-Containing Therapies: Medications such as Hormone Replacement Therapy (HRT), estrogen creams, or birth control pills should not be used with Letrozole. These products provide the very hormone that Letrozole is trying to eliminate, effectively neutralizing the drug's anti-cancer effects.
• Tamoxifen: While sometimes used sequentially, taking Tamoxifen and Letrozole simultaneously is generally avoided. Clinical data from the BIG 1-98 trial showed that co-administration of tamoxifen significantly reduces the plasma concentration of Letrozole by approximately 38%. This reduction may compromise the efficacy of Letrozole.

• Methotrexate: Some studies suggest that aromatase inhibitors may alter the clearance of methotrexate, potentially increasing the risk of toxicity. Close monitoring of blood counts is advised.
• Thalidomide: Concurrent use may increase the risk of blood clots (thromboembolism).

• CYP3A4 Inhibitors: Drugs that strongly inhibit the CYP3A4 enzyme (e.g., ketoconazole, clarithromycin, ritonavir) can theoretically increase Letrozole levels, although clinical studies have not shown this to be a major issue for most patients.
• CYP2A6 Inhibitors: Since Letrozole is also metabolized by CYP2A6, inhibitors of this enzyme could increase systemic exposure.

• Grapefruit and Grapefruit Juice: Grapefruit is a known inhibitor of the CYP3A4 enzyme. While no specific clinical trial has banned grapefruit with Letrozole, it is generally advisable to avoid large quantities to prevent potential increases in drug concentration.
• Soy and Isoflavones: High-dose soy supplements contain phytoestrogens, which may interfere with the estrogen-lowering goals of Letrozole therapy. While moderate dietary soy is usually considered safe, concentrated supplements should be discussed with an oncologist.

• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4. Taking it alongside Letrozole may speed up the metabolism of the drug, leading to lower-than-intended blood levels and reduced efficacy.
• Black Cohosh: Often used for hot flashes, its safety in patients with estrogen-sensitive cancers is debated. Patients should consult their oncologist before using it to manage Letrozole-induced hot flashes.

Letrozole can affect the results of several laboratory tests:

• Thyroid Function: Some patients may show slight alterations in TSH levels, though clinical hypothyroidism is rare.
• Liver Enzymes: Elevations in AST, ALT, and bilirubin may occur, mimicking liver disease.
• Lipids: Significant increases in total cholesterol and LDL may be seen on blood panels.

Management Strategy

For most interactions, the management strategy involves:

1. 1Screening: A thorough review of all medications before starting therapy.
2. 2Monitoring: Regular blood work to check for efficacy and toxicity.
3. 3Adjustment: If an interacting drug is necessary, the doctor may choose an alternative or monitor the patient more frequently.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.

Letrozole must NEVER be used in the following circumstances:

1. 1Pregnancy: Letrozole is a known teratogen (causes birth defects). It can cause fetal death or malformations such as shortened limbs and cardiac defects. It is strictly contraindicated for use in women who are currently pregnant.
2. 2Premenopausal Status: In women with functioning ovaries, the body will attempt to overcome the aromatase inhibition by producing more gonadotropins, which leads to increased ovarian estrogen production. This renders Letrozole ineffective for treating breast cancer in premenopausal women unless they are also taking an ovarian suppression drug (like leuprolide).
3. 3Hypersensitivity: Anyone with a known severe allergy to Letrozole or any of the inactive ingredients in the tablet (such as lactose or corn starch) must not take the medication.

These conditions require a careful risk-benefit analysis by a healthcare provider:

• Severe Hepatic Impairment: Due to the risk of significantly increased drug exposure, Letrozole should be used with extreme caution in patients with Child-Pugh Class C cirrhosis.
• Osteoporosis: Because Letrozole accelerates bone loss, patients with already fragile bones are at high risk for fractures. The benefits for cancer treatment usually outweigh the risks, but aggressive bone-protective therapy must be implemented.
• Severe Renal Impairment: Patients with a creatinine clearance below 10 mL/min should be monitored closely, as there is insufficient data on safety in this population.

While Letrozole is a non-steroidal inhibitor, patients who have had severe allergic reactions to other aromatase inhibitors (such as Anastrozole or Exemestane) should use Letrozole with caution, although there is no definitive evidence of cross-reactivity between the non-steroidal and steroidal classes.

> Important: Your healthcare provider will evaluate your complete medical history, including your menopausal status and bone health, before prescribing Letrozole.

Letrozole is classified by the FDA as pregnancy category X in many historical contexts, meaning the risks of use in pregnant women clearly outweigh any possible benefits. If a woman becomes pregnant while taking Letrozole for breast cancer, the drug must be stopped immediately. In fertility treatments, Letrozole is administered before conception occurs. Studies have shown that when used correctly for ovulation induction, the risk of congenital malformations is not significantly higher than in the general population; however, it must never be taken once a pregnancy is confirmed.

It is unknown whether Letrozole is excreted in human milk. Because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (including interference with the infant's hormonal development), women should not breastfeed while taking Letrozole and for at least 3 weeks after the final dose.

Letrozole is not recommended for use in children. Clinical trials in pediatric populations have been limited. There are significant concerns regarding the impact of estrogen suppression on bone growth and the timing of epiphyseal closure (the end of bone growth). Some off-label use exists for adolescent males with constitutional delay of growth, but this remains controversial and is not standard of care.

In clinical trials, approximately 45% of patients were 65 years of age or older. No overall differences in safety or effectiveness were observed between these patients and younger patients. However, elderly patients are at a higher baseline risk for osteoporosis and cardiovascular disease, making the monitoring of bone density and lipids particularly important in this demographic.

No dose adjustment is required for patients with mild to moderate renal impairment. For those with end-stage renal disease or those on dialysis, Letrozole should be used with caution as the drug's behavior in these systems has not been fully characterized.

Patients with mild to moderate liver impairment do not typically require a dose change. However, for those with severe hepatic impairment (Child-Pugh C), the systemic exposure to Letrozole is increased by approximately 95%. In these cases, a reduced dose or a modified dosing schedule (e.g., 2.5 mg every other day) is often recommended by specialists.

> Important: Special populations require individualized medical assessment and frequent monitoring to ensure the safe use of Letrozole.

Letrozole is a potent and highly selective non-steroidal inhibitor of the aromatase enzyme. It works by competitive binding to the heme iron of the cytochrome P450 unit of the enzyme. This prevents the conversion of androgenic precursors (primarily androstenedione and testosterone) into estrogens (estrone and estradiol). In postmenopausal women, this results in a reduction of serum estradiol, estrone, and estrone sulfate by 75% to 95% from baseline. This suppression is highly specific; Letrozole does not affect the synthesis of adrenal corticosteroids, aldosterone, or thyroid hormones.

In postmenopausal healthy volunteers, single doses of 0.1 mg, 0.5 mg, and 2.5 mg of Letrozole suppressed serum estrone and estradiol by 75-78% and 78% respectively. Maximum suppression is typically achieved within 48 to 78 hours. In patients with breast cancer, daily doses of 0.1 mg to 5 mg suppress plasma concentrations of estradiol by 88% to 98%. The dose-response relationship suggests that 2.5 mg is the optimal dose for maximal estrogen suppression.

| Parameter | Value |

|---|---|

| Bioavailability | ~99.9% |

| Protein Binding | ~60% (mainly albumin) |

| Half-life | ~48 hours (range 2-4 days) |

| Tmax (Time to peak) | 1 hour (fasted) to 2 hours (fed) |

| Metabolism | Hepatic (CYP3A4, CYP2A6) |

| Excretion | Renal (90% as metabolites) |

• Molecular Formula: C17H11N5
• Molecular Weight: 285.31 g/mol
• Solubility: Practically insoluble in water; soluble in organic solvents like ethanol and acetone.
• Description: Letrozole is a white to yellowish crystalline powder. It is chemically described as 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile.

Letrozole is classified as a third-generation non-steroidal aromatase inhibitor. It is part of the broader category of endocrine (hormonal) therapies for breast cancer. Related medications in this class include Anastrozole (Arimidex) and Exemestane (Aromasin). While Anastrozole is also non-steroidal, Exemestane is a steroidal inhibitor that binds irreversibly to the aromatase enzyme.